Phase 2 N=205 The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE
Chronic Kidney Disease
Primary: FGF23 — .047; -.003; .193; .138 pg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=61 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001
Anemia
Primary: Characterization of Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Events
Phase 2 N=50 Translocator Protein and Inflammation After Traumatic Brain Injury
Traumatic Brain Injury (TBI) · Healthy
Primary: Receptor Binding (Vt) — 2.53; 2.21; 3.21; 3.22 mL/cm^3
Phase 2 N=222 Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Number of Irritable Bowel Syndrome (IBS) With Predominantly Diarrhea (IBS-D) Participants Who Were Abdominal Pain Intensity (API) Weekly Responders at Week 12 — 27; 27…
Phase 2 N=11 First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
Multiple Myeloma
Primary: Average Absorbed Radiation Dose Estimates for Normal Tissues for Phase I Participants — 0.49 mSv/MBq
Phase 2 N=38 Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
PTSD
Primary: Change From Baseline to Visit 19 in CAPS-5 Total Severity Scores — -30.49 score on a scale
Phase 2 N=145 Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma Refractory · Diffuse Large B-cell Lymphoma Recurrent
Primary: Overall Response Rate (ORR) — 48.3 percentage of participants
Phase 2 N=28 A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Safety of NKTR-214 as Evaluated by Incidence of Drug-related Adverse Events (AEs) — 2; 8; 2; 1 events
Phase 2 N=811 An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Phase 2 N=142 A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs — 65; 66; 32; 28 Participants
Phase 2 N=60 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression
Bipolar Depression
Primary: Baseline and Week 12 Montgomery-Asberg Depression Rating Scale (MADRS) Scores — 29.61; 27.79; 18.64; 16.06 units on a scale
Phase 2 N=41 Tolerance Following Peanut Oral Immunotherapy
Peanut Allergy
Primary: Tolerance, Partial Tolerance, or Treatment Failure — 5; 0; 8; 0 Participants
Phase 2 N=28 TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Estrogen Receptor Positive Breast Cancer
Primary: Ki67 Expression — 15; 10 Percentage of cells with Ki67 expression — p==0.0023
Phase 2 N=64 Sulforaphane to Reduce Symptoms of Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase — 81.0; 81.5; 81.7; 79.7 score on a scale
Phase 2 N=109 Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
Primary: Percent Change in Urine Protein/Creatinine (Up/C) — -44.8; -18.5; -47.4; -33.1 percent change